BH-501242
/ BlossomHill Therap
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 17, 2026
Title: Design and discovery of BH-501242, a novel pan-KRAS on/off inhibitor targeting KRAS switch II pocket (#5120)
(GlobeNewswire)
- "BlossomHill Therapeutics...announced it will introduce its next-generation KRAS pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2026....Preclinical data demonstrate that BH-501242, a novel pan-KRAS inhibitor targeting the switch II pocket, potently inhibits a broad range of KRAS mutations, including G12D, G12V, and G12C, with sub-nanomolar cellular activity and robust tumor regression in multiple xenograft models."
Preclinical • Solid Tumor
1 to 1
Of
1
Go to page
1